Authorship Criteria, Contributorship, and Ethical Writing Practices

Authorship standards. Authorship confers credit and accountability. Policy should adopt widely recognized criteria such as those articulated by leading editorial groups: substantial contribution to conception/design or data acquisition/analysis/interpretation; drafting or critical revision for important intellectual content; final approval of the version to be published; and accountability for all aspects of the work. Require that all four conditions be met to qualify, and that contributors who do not meet all conditions be acknowledged transparently.

Contributorship taxonomy. Beyond the author list, mandate a standardized contributorship statement (for example, roles akin to the CRediT taxonomy) to describe who did what—conceptualization, methodology, investigation, formal analysis, data curation, writing–original draft, writing–review & editing, visualization, supervision, project administration, and funding acquisition. This improves transparency, clarifies accountability, and helps editors and readers understand sponsor and CRO roles.

Prohibited practices. Explicitly prohibit ghostwriting (uncredited authorship), guest or gift authorship (credit without qualifying contributions), and duplicate publication without clear justification and cross-reference. Require disclosure of medical writing support and funding, including the names and affiliations of writers and statisticians, and describe their roles. If a professional medical writer drafts content, their contribution should be acknowledged, and authors must retain control of all content and final approval.

Data access and verification. At least one author—typically the guarantor—must have had unrestricted access to the underlying data and the analysis code or outputs sufficient to verify results. Where data are held by a CRO or data platform, provide access arrangements (read-only data rooms, statistical review sessions, or verified analysis summaries) that allow authors to meet accountability obligations without compromising participant privacy or blinding.

Conflict-of-interest and funding statements. Require uniform disclosure forms from all authors and contributors, capturing financial relationships (employment, stock/stock options, consulting fees, grants), intellectual property interests, and non-financial conflicts. Ensure the funding statement states the sponsor’s role in design, conduct, analysis, and publication decisions. Editors and readers should be able to see precisely where the sponsor’s involvement began and ended.

Patient and public involvement. Where patients or caregivers contribute to study design, outcome selection, interpretation, or dissemination, acknowledge their roles and compensate fairly. Provide plain-language explanations of findings in parallel to scientific outputs, with numbers and messages synchronized. Maintain dignity and privacy; contributors should never be identifiable without explicit consent.

Corrections, retractions, and post-publication review. Establish a mechanism to issue corrections and, where warranted, retractions with clear rationales (analytical errors, duplication, ethical concerns). Maintain a public log of post-publication updates and ensure that registries and lay summaries are updated consistently. This keeps the scientific record coherent and improves trust after errors are discovered.

Reference norms. When codifying authorship expectations in SOPs, many sponsors cite editorial standards such as the guidance available from the International Committee of Medical Journal Editors. Align internal criteria to these norms while preserving flexibility for journal-specific requirements.

From Policy to Practice: Planning, Review, Timelines, and Consistency

Publication planning. Create a living plan that lists target journals and congresses, manuscript and abstract topics, responsible authors, and timelines tied to database locks and public results clocks. Plans should include primary, key secondary, safety, subgroup, health-economics, device usability, and methodological papers, plus systematic disclosure of negative and non-confirmatory analyses. Avoid salami slicing; specify how analyses cluster logically to prevent redundant publications.

Editorial independence and decision rights. Define who owns content decisions. Scientific leads and authors must retain control over analysis choices, discussion framing, and conclusions. Sponsor review should focus on factual accuracy, confidentiality, and legal compliance—not on suppressing or reshaping unfavorable results. If disagreements arise, record the scientific rationale and the final decision in a version-controlled system.

Alignment checks across records. Before submission, run a structured cross-walk: confirm that primary/secondary outcomes, arm names, time points, denominators, and key figures match the protocol, statistical analysis plan, results postings, and data sharing packages. Where analyses evolve (e.g., pre-specified sensitivity analyses or amendments), ensure changes are traceable, justified, and clearly described in the manuscript. Maintain a single “evidence pack” per output—tables, figures, code or shell, and sign-offs with the meaning of each signature (e.g., “Statistical accuracy approval”).

Preprints, conference abstracts, and embargos. Policies should clarify when preprints are appropriate, how they relate to journal submission, and how updates are flagged after peer review. For conferences, define abstract content standards (no selective reporting, methods transparency, and alignment with posted results) and how embargos interact with statutory disclosure clocks. Where journals require data or code availability statements, synchronize them with your data sharing governance to avoid contradictory promises.

Medical writing and statistical support. Specify qualifications for professional writers and statistical reviewers, including familiarity with trial design, estimands, and reporting guidelines. Writers help authors communicate clearly and consistently; they do not replace authorship. Statistical reviewers should verify method descriptions, reproduce key results where feasible, and confirm that reporting follows pre-specified plans.

Devices and diagnostics. For device and diagnostic manuscripts, include performance characteristics (sensitivity, specificity, AUC), human factors and usability results, and failure modes where relevant. Clarify versioning of hardware/firmware and the clinical context in which performance was measured. Bound claims tightly to the validated configuration to avoid over-generalization.

Decentralized and hybrid trials. When tele-visits, home health, or wearables are used, describe measurement conditions, identity and privacy safeguards, and how remote data were integrated. Provide enough operational context for reviewers to assess reliability without overwhelming the narrative with operational minutiae.

Negative and null results. State explicitly that negative, inconclusive, or non-primary outcomes will be submitted with the same urgency as positive findings. Editors are increasingly receptive to rigorous null results; your policy should reinforce that publication is about completeness and learning, not just positive signals.

Governance, Metrics, Risks, and a Ready-to-Use Checklist

Governance architecture. Establish a small Publications Steering Committee with representatives from Clinical, Biostatistics, Medical Writing, Patient Engagement, Legal/Privacy, and Quality. This body approves the plan, arbitrates authorship disputes, monitors timelines, and ensures consistency across outputs. Assign a Publications Operations Lead to run workflows, maintain evidence packs, and steward dashboards that surface bottlenecks before deadlines slip.

Auditable workflows. Use a version-controlled system for drafting and review. Capture who changed what and why, with timestamps and the meaning of each approval. Store conflict-of-interest forms, contributor statements, data access attestations, and final publisher proofs in pre-mapped TMF locations. Build “five-minute retrieval” drills into quality routines so any output can be traced from abstract to dataset rapidly.

Metrics that predict control. Measure what matters: percentage of primary manuscripts submitted within X days of database lock; proportion of negative/null outputs included in the plan; rate of registry–manuscript inconsistencies detected pre-submission; first-pass acceptance of required disclosures (conflicts, funding, data availability, contributorship); time from reviewer comments to resubmission; and recurrence rate of the same editorial or ethical findings. Treat repeated defects as triggers for corrective and preventive action with design changes (templates, checklists), not just retraining.

Risk controls. Identify red flags early: evidence that sponsor comments reshape conclusions, pressure to omit pre-specified outcomes, or reluctance to publish null results. Require escalation to the Steering Committee when such risks arise. Build guardrails for commercially sensitive information while keeping manuscripts scientifically coherent; when redaction is required in public documents, ensure the narrative remains intelligible and consistent with posted results and lay summaries.

Training and calibration. Provide concise, role-based modules for investigators, writers, statisticians, and sponsor reviewers. Include scenarios on authorship qualification, conflicts, duplicate publication, and handling of exploratory analyses. Calibrate expectations through sample cases where teams practice writing contributorship statements, disclosing funding and conflicts, and aligning a manuscript with registry outcomes and plain-language summaries.

Practical checklist (copy/paste into your SOP).

• Publication plan approved; negative and non-confirmatory outputs included; timelines tied to database lock and public disclosure clocks.
• Authorship criteria documented; contributorship taxonomy applied; medical writing and statistical roles defined and acknowledged.
• Conflict-of-interest, funding, and data/code availability statements completed for all authors.
• Evidence pack complete (tables/figures, shells or code, cross-walk to protocol/SAP/registries, approvals with meaning of signature).
• Preprint and conference policies followed; embargo and registry timelines reconciled; patient-facing materials synchronized.
• Independent statistical verification performed as appropriate; guarantor identified with documented data access.
• Journal reporting guidelines applied; device/diagnostic performance metrics included where relevant; claims bounded to data.
• Corrections/retractions pathway defined; public log for post-publication updates maintained; registries/PLS updated if manuscripts change interpretation.
• TMF locations pre-mapped; retrieval drill passed within five minutes from manuscript to underlying analyses.
• KPIs monitored monthly; repeat defects drive CAPA with design changes, not only retraining.

Bottom line. Publication policies and authorship criteria succeed when they promote completeness, independence, and coherence across technical, public, and patient-facing outputs. Anchor your system in internationally recognized expectations, document roles and decisions, align manuscripts with registries and results postings, and make every choice auditable. The reward is credibility with journals, readers, and regulators—and a scientific record worthy of the people who joined your trials.